Over the last few years, various monoclonal antibodies targeting immunological checkpoints such as CTLA-4, PD-1, and PD-L1 have been approved, each with its own mode of action. Manufacturers are concentrating their efforts on creating medications from many classifications to treat various disorders, from cancer to rare diseases. Monoclonal antibodies combined with chemotherapeutic drugs are increasingly being used to treat various malignancies. For instance, the United States Food and Drug Administration (FDA) approved Darzalex (daratumumab) in combination with pomalidomide and dexamethasone in 2017 to treat patients with multiple myeloma who had previously received two treatments.
Frequently Asked Questions
The market is segmented based on Segmentation, By Production Methods (In Vivo, In Vitro), Source (Murine, Chimeric, Humanized, Human, Others), Indication (Cancer, Autoimmune Diseases, Inflammatory Diseases, Infectious Diseases, Others), Route of Administration (Intravenous, Subcutaneous, Intravitreal, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2032
.
The Global Monoclonal Antibodies Market size was valued at USD 263.22 USD Billion in 2024.
The Global Monoclonal Antibodies Market is projected to grow at a CAGR of 13.4% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
